Indo Us Biotech Limited develops and manufactures pharmaceutical and healthcare products, including formulations and related products for domestic and international markets. Its portfolio benefits from the increasing demand for affordable healthcare products. Product development and manufacturing capabilities provide a foundation for expansion. Regulatory compliance and product quality remain important competitive factors. Expansion of its product portfolio and international presence can support long-term growth.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Beta |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 0.84 |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✗ Close above the 150- and 200-day averages ✗ 150-day above 200-day ✗ 200-day rising for a month ✗ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 60.31 ✗ Within 25% of the 52-week high · high 150.72 ✗ RS percentile 70 or more · RS 36 Minervini's trend template - the gate the scanner applies. | 2/8 | 2 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 4 - declining | |
| CAN SLIM | — C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 150.72 ✓ S more volume on up days than down days (50 sessions) · 2.16x ✗ L RS percentile 80 or more · RS 36 — I institutional sponsorship rising (FII + DII) · not yet collected for this stock ✗ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 37% William O'Neil's growth-leader checklist. | 1/4 | Weak |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✗ Close above the prior 55-session high · 90.88 ✓ Close above the prior 20-session high · 81.98 ✗ Close below the prior 20-session low (also a Turtle exit level) · 57.50 Turtle-inspired long breakout: the Turtle traders' entry channels only - no exits, stops or position sizing. | Breakout (20-day) | |
| Graham | Needs positive earnings and book value. | Not assessable |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDOUS this stock | +11.5 | +3.3 | -14.7 | -38.7 | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.84 |
| BLISSGVS | -12.1 | +44.1 | +140.8 | +326.5 | +669.3 | +478.2 | 50.3 | 5.77 | 11.5 | 16.8 | 9.65 | 0.00 | 28.0 | 6,878 | 1,005 | 142 | 12.9 | 1.10 |
| INDSWFTLAB | -7.1 | +60.4 | +172.3 | +267.0 | +344.0 | +532.6 | 55.6 | 2.38 | 3.2 | 3.9 | 2.66 | 0.01 | 30.0 | 3,291 | 665 | 57 | 6.8 | 0.80 |
| BAFNAPH | +42.5 | +93.6 | +249.0 | +227.1 | +429.1 | +247.8 | — | 11.37 | — | — | — | — | — | — | — | — | — | 0.34 |
| VENUSREM | -18.4 | -13.1 | +45.8 | +204.4 | +388.0 | — | 15.3 | 2.68 | 16.8 | 21.9 | 13.10 | 0.00 | 11.6 | 1,778 | 811 | 116 | 86.9 | 0.93 |
| MOREPENLAB | +4.0 | +127.1 | +197.6 | +159.7 | +278.8 | +144.6 | 49.1 | 5.52 | 7.9 | 10.1 | 5.11 | 0.16 | 40.1 | 6,881 | 1,951 | 140 | 2.6 | 1.47 |
| SHILPAMED | -9.1 | +54.0 | +128.5 | +158.1 | +450.0 | +214.7 | 61.0 | 7.03 | 9.8 | 11.4 | 6.94 | 0.25 | — | 18,221 | 1,682 | 297 | 15.3 | 0.88 |
| RUBICON | -1.8 | +1.9 | +63.8 | +153.0 | — | — | 88.2 | 20.07 | 22.4 | — | — | 0.20 | 57.9 | 25,865 | 1,936 | 288 | 17.7 | 0.37 |
| LAURUSLABS | +8.5 | +24.1 | +100.1 | +127.4 | +511.5 | +305.1 | 93.7 | 22.24 | 18.2 | 17.9 | 8.97 | 0.45 | 59.3 | 1.18L | 8,839 | 1,252 | 23.3 | 0.76 |
| ACUTAAS | +15.4 | +12.5 | +50.3 | +116.4 | — | — | 78.7 | 18.37 | 24.0 | 31.7 | 20.17 | 0.02 | 48.9 | 30,374 | 1,462 | 387 | 47.2 | 0.76 |
| ZIMLAB | +2.7 | +22.1 | +64.1 | +104.9 | +23.1 | — | 172.3 | 2.55 | 2.1 | 5.5 | 1.15 | 0.42 | 18.7 | 756 | 397 | 4 | 0.8 | 0.77 |
← All NSE stocks · More Pharma stocks